Barclays PLC Has $1.58 Million Holdings in Tandem Diabetes Care Inc (NASDAQ:TNDM)

Barclays PLC lowered its stake in shares of Tandem Diabetes Care Inc (NASDAQ:TNDM) by 76.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 41,562 shares of the medical device company’s stock after selling 136,656 shares during the quarter. Barclays PLC owned about 0.07% of Tandem Diabetes Care worth $1,578,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the stock. Bank of New York Mellon Corp increased its position in Tandem Diabetes Care by 314.6% during the second quarter. Bank of New York Mellon Corp now owns 204,679 shares of the medical device company’s stock worth $4,508,000 after acquiring an additional 155,314 shares during the period. US Bancorp DE increased its position in shares of Tandem Diabetes Care by 397.8% in the third quarter. US Bancorp DE now owns 2,489 shares of the medical device company’s stock worth $107,000 after purchasing an additional 1,989 shares during the period. Comerica Bank bought a new position in shares of Tandem Diabetes Care in the third quarter worth $209,000. Wells Fargo & Company MN increased its position in shares of Tandem Diabetes Care by 11.3% in the third quarter. Wells Fargo & Company MN now owns 26,968 shares of the medical device company’s stock worth $1,155,000 after purchasing an additional 2,734 shares during the period. Finally, Cambridge Investment Research Advisors Inc. bought a new position in shares of Tandem Diabetes Care in the third quarter worth $440,000. 82.58% of the stock is currently owned by institutional investors and hedge funds.

TNDM traded down $1.17 during trading on Monday, reaching $61.62. 971,411 shares of the company were exchanged, compared to its average volume of 1,997,110. The stock has a market capitalization of $3.62 billion, a price-to-earnings ratio of -24.16 and a beta of 0.68. Tandem Diabetes Care Inc has a 12-month low of $6.76 and a 12-month high of $74.81.

Tandem Diabetes Care (NASDAQ:TNDM) last issued its quarterly earnings data on Tuesday, February 26th. The medical device company reported $0.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.24. The business had revenue of $76.20 million for the quarter, compared to analysts’ expectations of $56.34 million. Tandem Diabetes Care had a negative return on equity of 67.92% and a negative net margin of 66.68%. The firm’s quarterly revenue was up 89.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.23) EPS. As a group, research analysts predict that Tandem Diabetes Care Inc will post -0.72 earnings per share for the current year.

In related news, EVP Brian B. Hansen sold 10,000 shares of Tandem Diabetes Care stock in a transaction on Friday, March 15th. The stock was sold at an average price of $72.00, for a total value of $720,000.00. Following the completion of the sale, the executive vice president now owns 11,381 shares of the company’s stock, valued at $819,432. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP David B. Berger sold 2,000 shares of Tandem Diabetes Care stock in a transaction on Wednesday, April 3rd. The stock was sold at an average price of $62.60, for a total value of $125,200.00. Following the completion of the sale, the executive vice president now directly owns 3,765 shares of the company’s stock, valued at approximately $235,689. The disclosure for this sale can be found here. In the last three months, insiders sold 353,300 shares of company stock valued at $22,135,999. Corporate insiders own 9.30% of the company’s stock.

A number of brokerages recently commented on TNDM. Bank of America raised their price target on Tandem Diabetes Care from $59.00 to $65.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 5th. ValuEngine cut Tandem Diabetes Care from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 28th. Oppenheimer raised their price target on Tandem Diabetes Care from $57.00 to $68.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 27th. Cowen lifted their target price on Tandem Diabetes Care from $40.00 to $60.00 and gave the company an “outperform” rating in a research report on Wednesday, February 27th. Finally, Craig Hallum lifted their target price on Tandem Diabetes Care from $59.00 to $70.00 and gave the company a “buy” rating in a research report on Wednesday, February 27th. Four analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $59.43.

ILLEGAL ACTIVITY NOTICE: “Barclays PLC Has $1.58 Million Holdings in Tandem Diabetes Care Inc (NASDAQ:TNDM)” was first posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://www.baseballdailydigest.com/news/2019/04/15/tandem-diabetes-care-inc-tndm-stake-decreased-by-barclays-plc.html.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.

Featured Article: Different Types of Derivatives

Institutional Ownership by Quarter for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.